Novartis has confirmed that it will shed around 8,000 jobs across its global operations as part of a restructure first announced in April.
Novartis To Cut 8,000 Jobs In Global Restructure
Follows Through On Plan For Leaner Organization
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.
More from Business
More from Scrip
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.